Alchemab publication and NeurIPS Machine Learning in Structural Biology workshop. Click to read more.
Michelle Sidor and Iosif Pediaditakis presented the following posters: ‘Human-derived CD33 antibody ATLX-1088, a potent stimulator of microglial pharmacology’ and ‘Netrin-1 and neurodegenerative diseases: Unraveling Therapeutic Avenues’. Learn More
Listen to our CEO, Young Kwon discuss Alchemab’s innovative platform and its novel approach to drug discovery on the pharmaphorum podcast. Learn More.
Listen to CEO Young Kwon chat with Wells Fargo analyst Derek Archila at the Wells Fargo 2023 Healthcare Conference. Live webcast scheduled for Sep 7, 2023 at 4:30 pm ET. Please click here to view.
Our CEO Young Kwon was delighted to speak with Richard Staines of the Optimum Perspectives Podcast on how Alchemab is revolutionizing antibody drug discovery with a novel alternative to the classic “choose a target” approach. Listen Here.
Alchemab’s Sandrine Legg, Director of Phenotypic Screening presented data on a potential first-in-class disease-modifying therapeutic for Alzheimer’s disease at the Antibody Industrial Symposium in Tours, France on 22 June 2023. See the attached presentation to learn more.